期刊
JOURNAL FOR IMMUNOTHERAPY OF CANCER
卷 10, 期 7, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2022-005065
关键词
Immunotherapy; Tumor Microenvironment; Programmed Cell Death 1 Receptor; Oncolytic Virotherapy; Drug Therapy; Combination
资金
- Zhejiang Provincial College Student Science and Technology Innovation Activity Plan-College Student Innovation and Entrepreneurship Incubation Program (Young Talent Program) [2022R40122]
- National Natural Science Foundation of China [31970696, 81502975, 82188102]
- Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholar [LR22H160010]
- National Key Research and Development Program of China [2019YFC1316000]
Oncolytic peptides are highly effective in remodeling the tumor microenvironment and enhancing anticancer immunity by inducing immunogenic cell death. A recent study shows that LTX-315 inhibits PD-L1 expression via ATP11B, thereby enhancing the effectiveness of cancer immunotherapy by targeting the PD-1/PD-L1 axis. This commentary discusses the broad effects and perspectives of oncolytic peptides on anticancer immunity, as well as the potential issues and directions in cancer immunotherapy.
Oncolytic peptides are highly effective on remodeling the tumor microenvironment and potentiating the anticancer immunity through multiple mechanisms, particularly by inducing immunogenic cell death. Intriguingly, a recent study demonstrates that LTX-315, one of the most promising and extensively studied oncolytic peptides, inhibits PD-L1 expression via ATP11B, thus enhancing the effectiveness of cancer immunotherapy by targeting the PD-1/PD-L1 axis. Therefore, this commentary discusses the broad effects and perspectives of oncolytic peptides on anticancer immunity, further highlighting the potential issues and directions of oncolytic peptides in cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据